A GREAT interview by Peter Switzer, page-4

Yep, it was technically a phase 1/2a trial.

Investigator initiated, yes. But there is nothing wrong with that (especially at this point in time and for this combination). It is anzctr registered, it shows that cancer physicians are interested, it costs Nox less, and adds weight to the overall body of evidence of both safety and efficacy. All positive, particulary considering Veyonda + Lu-PSMA is not the main game by any stretch. It could now be considered a feasible backup plan which is always nice to have on a smallcap biotech. (If Pharmorage, Nyrada, and a pipeline of new compounds is not enough of a backstop for you).